Surrozen Inc.

SRZN | NASDAQ

Price Alert Chart Builder DCF Calculator

$16.62

+$0.07 (+0.42%)

Sep 21, 2026, 12:39 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.42%

(1D)

Rating

Updated: Aug 18, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $124.31M

1D Range

16.44 17.45

52W Range

11.39 35

Valuation (TTM)

PE -0.37

PB -0.57

EV/EBITDA -0.08

Valuation (NTM)

Forward PE N/A

Forward PEG 0.01

Price Target $44

Cash Flow

FCF Yield -28.3%

SBC Adj. FCF Yield -33.9%

SBC Impact -20.0%

Margins

Gross Margin 99.4%

Operating Margin -385.3%

FCF Margin -303.9%

Growth (CAGR)

Revenue 3Y | 5Y -2.7% | 31.6%

Dil EPS 3Y | 5Y -42.4% | -17.1%

FCF 3Y | 5Y -5.6% | 17.4%

Returns

ROA -287.3%

ROE 187.6%

ROIC -40.8%

Financial Health

Net Cash

$102.04M

Current Ratio 12.14

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics t...

Sector Healthcare

Industry Biotechnology

Employees 44

IPO Date Jan 10, 2021

Website www.surrozen.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 6, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$44

Upside

+164.74%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞